Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3045697 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3045697 | EXPERIMENTAL | Escalating dose (0.1 milligrams \[mg\] up to 100 mg) of LY3045697 administered once daily, orally, for 8 days in 2 of 3 dosing periods |
| Spironolactone | ACTIVE_COMPARATOR | 25 mg spironolactone administered once daily, orally, for 8 days in up to 1 of 3 dosing periods |
| Placebo | PLACEBO_COMPARATOR | Placebo matching LY3045697 administered once daily, orally for 8 days in up to 1 of 3 dosing periods |
| Group 1 | EXPERIMENTAL | Period 1: 0.1 milligrams (mg) LY3045697 administered once orally or matching placebo administered once orally. Period 2: 1 mg LY3045697 administered once orally or matching placebo administered once orally. Period 3: 10 mg LY3045697 administered once orally or matching placebo administered once orally. |
| Group 2 | EXPERIMENTAL | Period 1: 0.3 mg LY3045697 administered once orally or matching placebo administered once orally. Period 2: 3 mg LY3045697 administered once orally or matching placebo administered once orally. Period 3: 30 mg LY3045697 administered once orally or matching placebo administered once orally. |
| Group 3 | EXPERIMENTAL | Period 1: 100 mg of LY3045697 administered once orally or matching placebo administered once orally. Period 2: 300 mg of LY3045697 administered once orally or matching placebo administered once orally (via split delivery over a 15-minute period). |
| Name | Type | Description |
|---|---|---|
| LY3045697 | DRUG | Administered as oral solution |
| Placebo | DRUG | Administered as oral solution |
| Spironolactone | DRUG | Administered as capsule |
Inclusion Criteria: * Healthy men and women of non-child bearing potential as determined by medical history and physical examination * Male participants must agree to use a medically accepted method of contraception with all sexual partners during the study and for 90 days after the end of the fina...
LY3045697 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in Phase 1 clinical trials in healthy adult volunteers, and no therapeutic indication has been disclosed. Both completed trials took place in the Netherlands and evaluated the drug in participants aged 18 years and older.
LY3045697 is made and developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored both Phase 1 trials of the compound, which were conducted in the Netherlands in healthy volunteers.
LY3045697 is in Phase 1 development. Two Phase 1 trials have been completed, and no later-stage trials are listed. The studies enrolled a combined 51 healthy participants, and the compound remains investigational rather than approved for any use.
Two completed Phase 1 trials have studied LY3045697. NCT01821703 evaluated multiple oral doses in 24 healthy participants, and NCT01750853 studied the drug in 27 healthy participants. Both were conducted in the Netherlands, were randomized, double-blind, and placebo-controlled, and enrolled adults aged 18 years and older.
Both LY3045697 trials were Phase 1 studies in healthy volunteers conducted in the Netherlands. NCT01821703 tested multiple oral doses in 24 participants, while NCT01750853 enrolled 27 participants. Each study used a randomized, double-blind, placebo-controlled design, and both have been completed.